盐酸莫西沙星治疗慢性阻塞性肺疾病急性加重期的疗效及安全性

目的 探讨盐酸莫西沙星序贯疗法治疗慢性阻塞性肺疾病急性加重期的临床疗效及安全性。方法 选取200例慢性阻塞性肺疾病急性加重期的患者，随机分为对照组和观察组，对照组静脉给予盐酸莫西沙星氯化钠注射液治疗，观察组采用莫西沙星序贯疗法进行治疗，前5日静脉给予盐酸莫西沙星氯化钠注射液，病情好转后口服盐酸莫西沙星片，考察两组治疗前、后肺功能指标参数及血液中IL-8、TNF-α水平，比较两组的临床疗效和安全性。结果 经治疗后，观察组临床总有效率为94.0%，与对照组的95.0%比较，差异无统计学意义（χ2=0.0481，P>0.05）；两组患者的肺功能指标参数与治疗前比较，差异有统计学意义（P＜0.05），但观察组改善程度与对照组比较，差异有统计学意义（P＜0.05）；两组患者血液中IL-8、TNF-α水平与治疗前比较，差异有统计学意义（P＜0.05），观察组与对照组比较，差异无统计学意义（P>0.05）；观察组不良反应发生率8.0%与对照组17.0%比较，差异有统计学意义（χ2=1.8514，P＜0.05）。结论 采用序贯疗法治疗慢性阻塞性肺疾病，具有安全、有效等优点，有较大的临床推广意义。

The efficacy and safety of Moxifloxacin hydrochloride in the treatment of acute exacerbation of chronic obstructive pulmonary disease

Objective To investigate the clinical efficacy and safety of moxifloxacin hydrochloride-based sequential therapy in the treatment of acute exacerbation of chronic obstructive pulmonary disease（COPD）．Methods Two hundred of patients with acute exacerbation of COPD cases were randomly divided into the control group or observation group．The control group was given intravenous injection with moxifloxacin hydrochloride and sodium chloride，while the observation group was treated with moxifloxacin-based sequential therapy intravenously for the first 5 days followed by oral administration of moxifloxacin hydrochloride after their conditions were improved．The pulmonary function parameters as well as serum levels of IL-8 and TNF-α before and after treatment were observed，and the clinical efficacy and safety were compared between the two groups．Results The total efficiency in the observation group was 94% compared with the 95% in the control group（χ2=0.0481，P>0.05）．Significant improvements in pulmonary function parameters and serum levels of IL-8 and TNF-α were seen in both groups after treatment（Ps0.05）between the two groups．The incidence of adverse reactions was 8% vs 17% in observation group vs control group respectively，with statistically significant differences（χ2=1.8514，P<0.05）．Conclusion Sequential therapy with moxifloxacin is effective and safe in the treatment of COPD．